01 / 05
AACR Reports Great Progress Against Pediatric Cancer

American Association for Cancer Research | Noncommunicable Disease

AACR Reports Great Progress Against Pediatric Cancer

“Decades of research, collaboration, advocacy, and legislative and policy actions have transformed the outlook for cancers affecting children and adolescents. According to the AACR Pediatric Cancer Progress Report 2025:

  • In the United States, the five-year survival rate for all pediatric cancers combined has increased from 63% in the mid-1970s to 87% in 2015-2021.
  • Pediatric cancer mortality in the United States declined by 57% between 1970 and 2000, and by a further 19% from 2001 to 2023, reflecting advances in risk-stratified therapy, precision medicine, and supportive care.
  • Over the past few decades, research has uncovered the unique biological underpinnings of pediatric cancers, which are rare compared with adult cancers and are biologically distinct in their cellular origins, genomic drivers, tumor types, and therapeutic vulnerabilities.
  • Between 2015 and 2025, the U.S. Food and Drug Administration (FDA) approved more than 20 molecularly targeted therapies and more than 10 immunotherapies for pediatric cancers. Indeed, the proportion of drugs approved specifically for pediatric use rose from 5.9% between 2012-2016 to 13.8% between 2017-2021. While these numbers are significantly lower than what has been approved for adult cancers, the new treatments have been transformative for certain patients.
  • Advances in precision medicine not only have led to new anticancer therapeutics but also have allowed clinicians to tailor treatment intensity based on the molecular profile of a child’s or adolescent’s cancer, reducing therapy intensity for pediatric patients with a favorable disease profile and increasing it for pediatric patients with a higher risk of recurrence.
  • Technologies such as gene editing, liquid biopsy, and artificial intelligence are deepening our understanding of pediatric cancers and paving the way for additional breakthroughs.”

From American Association for Cancer Research.

Nature | Noncommunicable Disease

Gene Therapy Trial Cuts Seizures in Three Epilepsy Patients

“Three people with epilepsy resistant to drug treatment saw the number of seizures they had per month fall by more than 90%, after gene-laden viruses were infused directly into their brains as part of an early-stage clinical trial.

In each participant, the gene therapy was precisely targeted to a small patch of brain tissue that was the source of their seizures. The viruses carried a gene that makes neurons sensitive to a specific drug, which works like a dimmer switch for the therapy. By combining gene therapy with a drug — an approach known as chemogenetics — researchers can adjust a treatment’s potency, which is not possible with other types of gene therapy. The trial participants did not experience serious side effects.”

From Nature.

Medical Xpress | Noncommunicable Disease

CAR T May Improve Mobility in Stiff Person Syndrome

“New research led by the University of Colorado Anschutz is offering hope to people living with stiff person syndrome (SPS), showing that a CAR T-cell therapy may help change the course of the disease….

SPS is a rare, progressive autoimmune neurological disease that causes debilitating muscle stiffness, painful spasms and difficulty walking. An estimated 80% of patients eventually require walking assistance or a wheelchair, and many face a risk of permanent disability…

One year after receiving a single treatment of the experimental therapy, patients with SPS demonstrated significant improvements in mobility, completing a 25-foot walking test in nearly half the time it took before treatment. Also, two-thirds of patients who initially needed walking aids were able to complete a walking test without assistance. Beyond walking improvements, patients also experienced lasting reductions in muscle stiffness, sensitivity to stimuli and overall disability.”

From Medical Xpress.

The ASCO Post | Noncommunicable Disease

mRNA Combo Cuts High-Risk Melanoma Relapse

“Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract LBA1). The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with pembrolizumab alone.”

From The ASCO Post.

Nature | Noncommunicable Disease

Prime Editing Used in a Patient for First Time

“A powerful gene-editing technique has been used to edit DNA directly in a person’s body — the first known instance of such a treatment.

The milestone treatment is part of a clinical trial of prime editing, a technique that can alter DNA with more precision than standard CRISPR–Cas9 methods can. In this case, prime editing was used to treat a condition called Wilson’s disease by rewriting DNA in liver cells, to erase a mutation that prevents them from eliminating excess copper.

Prime Medicine, a biotechnology company in Cambridge, Massachusetts, announced that it had treated the first person in its trial earlier this month. It expects to announce the first results from the study next year.”

From Nature.